Related Experiment Video

Updated: Jun 27, 2026

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells
10:28

Flow Cytometry-based Drug Screening System for the Identification of Small Molecules That Promote Cellular Differentiation of Glioblastoma Stem Cells

Published on: January 10, 2018

PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells

W Chearwae1, J J Bright

  • 1Neuroscience Research Laboratory, Methodist Research Institute at Clarian Health, Indianapolis, IN, USA.

British Journal of Cancer
|November 20, 2008
PubMed

Insights

Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists inhibit brain tumour stem cell growth and expansion. These findings highlight PPARgamma agonists as a potential therapeutic strategy for targeting brain tumours.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Biology

Background:

  • Brain tumour stem cells (BTSCs) drive glioblastoma growth and recurrence.
  • Peroxisome proliferator-activated receptor gamma (PPARgamma) agonists show promise against glioblastoma cells.
  • The effect of PPARgamma agonists on BTSCs remains largely unknown.

Purpose of the Study:

  • To investigate the effects of PPARgamma agonists on brain tumour stem cells.
  • To determine if PPARgamma agonists can inhibit BTSC proliferation and expansion.
  • To elucidate the molecular mechanisms underlying PPARgamma agonist action on BTSCs.

Main Methods:

  • Generation of gliospheres enriched in CD133+ BTSCs from U87MG and T98G cells.
  • In vitro treatment of gliospheres with PPARgamma agonists (15d-PGJ2, all-trans retinoic acid).
  • Assessment of gliosphere formation, cell proliferation, cell cycle, apoptosis, and signaling pathway inhibition (Tyk2-Stat3).

Main Results:

  • PPARgamma agonists reversibly inhibited gliosphere formation.
  • PPARgamma agonists dose-dependently inhibited glioma and gliosphere cell proliferation and expansion.
  • PPARgamma agonists induced cell cycle arrest and apoptosis, linked to inhibition of EGF/bFGF signaling via Tyk2-Stat3 and PPARgamma expression.

Conclusions:

  • PPARgamma agonists effectively regulate the growth and expansion of brain tumour stem cells.
  • PPARgamma agonists demonstrate potential as a therapeutic approach for brain tumours by targeting BTSCs.
  • Targeting PPARgamma offers a novel strategy for glioblastoma treatment.

More Related Videos

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens09:26

Method for Novel Anti-Cancer Drug Development using Tumor Explants of Surgical Specimens

Published on: July 29, 2011

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice08:11

A Simple Guide Screw Method for Intracranial Xenograft Studies in Mice

Published on: September 26, 2011

Related Concept Videos

Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
GPCRs Regulate Adenylyl Cylase Activity01:09

GPCRs Regulate Adenylyl Cylase Activity

Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of cells.
Two...